Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”

New treatment options especially of solid tumors including for metastasized prostate cancer (PCa) are urgently needed. Recent treatments of leukemias with chimeric antigen receptors (CARs) underline their impressive therapeutic potential. However CARs currently applied in the clinics cannot be repea...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Feldmann, Anja, Arndt, Claudia, Bergmann, Ralf, Loff, Simon, Cartellieri, Marc, Bachmann, Dominik, Aliperta, Roberta, Hetzenecker, Mirjam, Ludwig, Florian, Albert, Susann, Ziller-Walter, Pauline, Kegler, Alexandra, Koristka, Stefanie, Gärtner, Sebastian, Schmitz, Marc, Ehninger, Armin, Ehninger, Gerhard, Pietzsch, Jens, Steinbach, Jörg, Bachmann, Michael
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5458214/
https://ncbi.nlm.nih.gov/pubmed/28404896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15572
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares